Summit Therapeutics Inc. - ADR
$13.50
$0.42
(3.21%)
As on 12-Jun-2026 13:41EDT
Market cap
$11,464 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
21
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.7 %
-
ROCE
-263 %
-
Industry P/E
--
-
EV/EBITDA
-5.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
776,162,645
10 Years Aggregate
CFO
£-341.32 Mln
EBITDA
£-348.02 Mln
Net Profit
£-891.55 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Summit Therapeutics - ADR
| -22.8 | -27.7 | -16.0 | -31.1 | 97.6 | 14.6 | 3.7 |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P 100
| 5.4 | -1.1 | 9.4 | 23.6 | 22.0 | 13.6 | 14.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Summit Therapeutics - ADR
| -2.0 | 573.1 | -38.6 | 58.0 | -42.8 | 193.8 | 39.1 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Summit Therapeutics - ADR
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific... antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida. Read more
-
Co-CEO & Executive Chairman
Mr. Robert W. Duggan
-
Co-CEO & Executive Chairman
Mr. Robert W. Duggan
-
Headquarters
Miami, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Summit Therapeutics - ADR
What is the current share price of Summit Therapeutics Inc - ADR Today?
The share price of Summit Therapeutics Inc - ADR is $13.50 (NASDAQ) as of 12-Jun-2026 13:41 EDT. Summit Therapeutics Inc - ADR has given a return of 97.59% in the last 3 years.
What is the current PB & PE ratio of Summit Therapeutics Inc - ADR?
Since, TTM earnings of Summit Therapeutics Inc - ADR is negative, P/E ratio is not available.
The P/B ratio of Summit Therapeutics Inc - ADR is 20.98 times as on 05-Jun-2026, a 415 premium to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-12.12
|
26.75
|
|
2024
|
-72.58
|
41.30
|
|
2024
|
--
|
--
|
|
2023
|
-3.35
|
26.32
|
|
2023
|
--
|
--
|
What is the 52 Week High and Low of Summit Therapeutics Inc - ADR?
The 52-week high and low of Summit Therapeutics Inc - ADR are Rs 30.98 and Rs 12.55 as of 13-Jun-2026.
What is the market cap of Summit Therapeutics Inc - ADR?
Summit Therapeutics Inc - ADR has a market capitalisation of $ 11,464 Mln as on 05-Jun-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Summit Therapeutics Inc - ADR?
Before investing in Summit Therapeutics Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.